Abstract
Allos Therapeutics Inc is developing the hemoglobin allosteric modifier efaproxiral as a potential radiosensitizer and chemotherapy enhancer in cancer therapy.
MeSH terms
-
Aniline Compounds / adverse effects
-
Aniline Compounds / chemical synthesis
-
Aniline Compounds / pharmacology*
-
Aniline Compounds / therapeutic use
-
Animals
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Contraindications
-
Humans
-
Neoplasms / radiotherapy*
-
Propionates / adverse effects
-
Propionates / chemical synthesis
-
Propionates / pharmacology*
-
Propionates / therapeutic use
-
Radiation-Sensitizing Agents / adverse effects
-
Radiation-Sensitizing Agents / chemical synthesis
-
Radiation-Sensitizing Agents / pharmacology*
-
Radiation-Sensitizing Agents / therapeutic use
-
Structure-Activity Relationship
Substances
-
Aniline Compounds
-
Propionates
-
Radiation-Sensitizing Agents
-
efaproxiral